Bold News report
Origin articleStored source

FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned

The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.

NPR News By Sydney Lupkin Captured Aug 1, 2026, 11:05 AM
Read the original Read Bold's report
Captured text

Source excerpt

387 extracted characters

The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market.

The decision is expected to reverberate throughout the biotech industry.

The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market.

The decision is expected to reverberate throughout the biotech industry.

Bold News stores the normalized extraction for evidence and analysis. This public wrapper shows a limited excerpt; use the original link for the publisher's complete presentation.